Cancer Res (2022) 82 (22_Supplement): PR006.

Cancer Res (2024) 84 (17_Supplement): A062.

Abstract. Most bladder cancers are poorly responsive to immune checkpoint blockade (ICB). With the need to define mechanisms of de novo resistance, including contributions from the tumor ...

Institute of TCM-X/MOE Key Laboratory of Bioinformatics, Bioinformatics Division, BNRist/Department of Automation, Tsinghua University, Beijing, China.

1Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, Montpellier, France.

1Adult Stem Cell Research Center and Research Institute for Veterinary Science, Seoul, Republic of Korea.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, and Department of Medicine, Harvard Medical School, Boston, ...

1Department of Oncology, University of Lausanne, Lausanne, Switzerland.

1Genentech, Inc., South San Francisco, CA. Search for other works by this author on: ...

Cancer Res (2022) 82 (12_Supplement): 5462.

Divarasib plus cetuximab is well tolerated in patients with KRAS G12C-positive colorectal cancer.

Search for other works by this author on: ...